All In Biotech

NDA 205382 · Glaxo Grp England

Incruse Ellipta

Umeclidinium Bromide · Inhalation

Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Apr 30, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

103

39 Phase 3, 4 recruiting

FAERS reports

9,060

4,828 serious, 661 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2025.

Umeclidinium ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Umeclidinium ELLIPTA is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 )

Mechanism: Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INCRUSE ELLIPTA · UMECLIDINIUM BROMIDE EQ 0.0625MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Umeclidinium" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,437
  • drug ineffective781
  • cough735
  • asthma640
  • pneumonia578
  • wrong technique in device usage process547
  • chronic obstructive pulmonary disease420
  • fatigue392
  • product dose omission issue354
  • death344
  • wheezing341
  • headache334

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20122
20132
20146
201599
2016636
2017870
20181,173
20191,241
20201,186
2021767
2022672
2023622
2024679
2025584
2026520

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Incruse Ellipta (Umeclidinium Bromide)

2024 spending

$376M

Beneficiaries

185,597

852,329 claims

Per beneficiary

$2,025

$11.36 per unit

View as table
YearSpending
2020$605,138,195
2021$555,719,848
2022$498,890,589
2023$456,391,929
2024$375,858,548

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 144 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.